Indeed, the recent EMBER-3 trial demonstrated that imlunestrant, a novel oral selective estrogen receptor degrader, showed superior efficacy compared to standard endocrine therapy in endocrine therapy-pretreated/ER+/HER2- advanced breast cancer patients harboring ESR1 mutations 64. Here, ESR1 is linked to breast cancer.